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“Success consists of going from failure to failure without the loss of enthusiasm” 




The failure to translate novel cardioprotective therapies tested in pre-clinical studies into the 
clinical setting for patient benefit can be attributed to a number of factors at different stages of the 
research process. This review focuses on the evidences and the gaps with regard to the translational 
journey of cardioprotective interventions. Gaps are classified into 3 main groups: 1) those related to 
pre-clinical studies, 2) those associated with the validation of infarct size as a good surrogate and 3) 
those based on design and interpretation of randomized clinical trials on cardioprotection. Addressing 
these gaps might increase the chances to successfully translate cardioprotective therapies into 








Acute myocardial infarction presenting as ST-segment elevation (STEMI) is the result of abrupt 
occlusion of an epicardial coronary artery, usually due to a sudden rupture of an atherosclerotic 
plaque. Early reperfusion by primary percutaneous coronary intervention (PPCI) limits myocardial 
infarct size (IS) and changes the fate of the myocardium at risk[1]. However, the process of restoring 
blood flow to the ischemic myocardium induces additional myocardial damage, known as 
“myocardial ischemia-reperfusion injury (IRI)”[2], that negatively impacts on IS and on mortality 
rates.  
In 1971, Braunwald et al proposed that the extent and severity of tissue damage after coronary 
occlusion could be modified by therapeutic manipulations applied during ischemia[3]. This work was 
the starting signal for several studies testing therapies designed to limit myocardial IS, also known as 
cardioprotective therapies. Although cardiovascular research in the 1970s was dominated by 
interventions aimed at limiting IS by pharmacotherapy in the absence of reperfusion (pre-
thrombolytic era), the concept of cardioprotection eventually evolved to include therapies designed to 
limit myocardial injury during ischemia and reperfusion [4]. 
Cardioprotective therapies might be applied in a wide spectrum of patients[2]. Nevertheless, this 
review focuses on those presenting with a STEMI treated by PPCI. Many interventions limiting 
myocardial IRI and reducing IS in experimental animal studies have been tested in this setting. 
Promising results in a number of “proof of concept” studies have been obtained with regard to their 
myocardial  infarct-sparing effect, however a few disappointing results have also been raised in terms 
of clinical outcomes benefit (Table 1).  
The failure to translate novel cardioprotective therapies discovered in pre-clinical studies into the 
clinical setting for patient benefit can be attributed to a number of factors at different stages of the 
research process. This review summarizes the evidences and the gaps with regard to the translational 
journey on cardioprotection. The aim is to note deficiencies and encourage improvements in the 
translation of cardioprotective therapies, classifying the gaps into 3 main groups: 1) those related to 
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pre-clinical studies, 2) those associated with the validation of IS as a good surrogate, and 3) those 
based on design and interpretation of randomized clinical trials (RCTs) on cardioprotection, including 
all the uncontrolled factors in the clinical setting.  
 
2. The pre-clinical gap 
Most of our knowledge about acute myocardial infarction (AMI) is derived from pre-clinical 
studies, although experimental animal models are used as approximations of human pathophysiology 
and it is fair to acknowledge that they present many limitations.  
2.1. Myocardial IRI model 
Remarkable differences exist between animal models and patients with STEMI, as seen in Table 
2. For instance, animals do not have atherosclerosis and the experimental infarct is caused by external 
compression or ligation of the artery, lacking the potential for embolization. Reperfusion in 
experimental models is usually successful and shorter than those registered in patients[5]. Moreover, 
the duration of reperfusion used in experimental models of acute IRI varies with the model, while in 
STEMI patients reperfusion is unlimited and IS assessment may occur several days after reperfusion. 
Time of IS evaluation is important not only because myocardial IS depends on both the duration of 
ischemia and the length of the reperfusion period[6], but also because the tissue response to IRI 
progresses dynamically over time, following a bimodal pattern as has been recently described[7]. 
2.2. Animal models  
Differences in animal physiology should be considered when attempting to translate an 
intervention[8]. Jones et al[9] in the framework of the CAESAR (Consortium for preclinical 
assessment of cARdioprotctive therapies) initiative described a species-related effect-size gradient 
when ischemic preconditioning (IPC) was applied, stressing the fact that successful extrapolation of 
animal results into clinics might depend on the species being evaluated. As a general rule, rodent 
models are optimal when testing a novel therapy and trying to identify  potential mechanisms, whilst 
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large-animal models, with a much closer match to human physiology, are more useful as a first step 
prior to performing proof-of-concept studies in the clinical arena[5].  
2.3. Reductionist models 
The essence of performing experiments in animal models is to effectively control variables in 
order to examine the real effect of any intervention. However, in the clinical setting, new 
cardiovascular medications are commonly tested on a background of guidelines and recommended 
therapies that include the standard of care[10,11].   
In laboratory bench models, a single intervention therapy is studied without the background of 
other therapies. This reductionist approach has provided novel mechanistic understanding, but does 
not adequately represent actual clinical situations. Hence, the effects of background medications are 
frequently overlooked and the expected effects of any particular cardioprotective therapy combined 
with the other are largely unknown. Interestingly, the co-application of two or more drugs might have 
a synergistic effects. Although the study of combining medications has not been properly addressed, 
some studies have reported benefits. For instance, Downey et al reported synergistic effects when 
applying three different interventions in rats[12], and a recent clinical study by Eitel et al reported 
enhanced cardioprotective effects when remote ischemic conditioning (RIC) and ischemic 
postconditioning (IPOST) were co-applied compared to separate administration of these interventions 
[13]. Further, the concomitant activation of two parallel and different signalling pathways conferring 
additional cardioprotection has been described by Bell et al[14]. 
A large body of literature suggests that co-morbidities such as diabetes, hypercholesterolemia, 
hypertension or aging can have substantial impact on the effectiveness of cardioprotective 
interventions. Despite their prevalence in the clinical setting, many pre-clinical studies do not 
adequately represent these and other co-morbid conditions.  
Future animal studies on cardioprotection (especially prior to clinical trial) will have more chance 
to be translated if conducted on a background of standard medication and co-morbidities[15]. 
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Nevertheless, reductionist models are still very important to develop an improved understanding of 
cardioprotective signalling and can act as a good initial screening model. 
2.4. Reproducibility and reporting 
Concerns have been raised lately on reproducibility and reporting the results in preclinical 
studies[16]. Not all research findings are reproducible and it is doubtful that the beneficial effects of 
any specific cardioprotective therapy would be replicated in the complex clinical setting if the results 
were not reproducible in the highly controlled experimental setting. The problem is magnified by the 
bias towards the publication of positive results and by the lack of formal request by journals of pre-
specified protocol design, as it happens with randomized clinical trials.  
The lack of reproducibility of scientific papers is an unresolved problem that might have some 
causes[17], such as the differences in experimental setting and protocols between (and even within) 
laboratories and the occasional lack of a full and comprehensive methods section allowing results to 
be reproduced by others .  
Several initiatives by investigators could  help address the issue of reproducibility of data and 
improve the quality of reporting in scientific publications. If the experimental data is inconsistent 
and/or insufficient, performing meta-analyses might be a good method to measure whether a 
cardioprotective effect is robust enough to be tested in randomized clinical trials (RCT). Whilst IPC 
has been shown to have a consistent effect in a large meta-analysis[18], other therapies have shown 
less solid results in meta-analyses based on pre-clinical studies. For instance, in a meta-analysis of 20 
in vivo experimental studies in IRI animal models[19], the overall IS-reducing effect of cyclosporine  
was shown to be remarkably variable with no overall effect observed in swine models. This meta-
analysis would be of great value before conducting clinical outcomes studies that subsequently have 
shown neutral results. A recent meta-analysis [20] has shown a positive effect of adenosine treatment 
on heart failure outcome in STEMI patients when intracoronary adenosine is administered as an 
adjunct to reperfusion, generating a hypothesis which could be confirmed by an adequately designed 
large-scale clinical trial. Thus, in the clinical setting, we might take advantage of published studies to 
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consolidate data into large meta-analyses in which variables not addressed by each single study can be 
observed, for e.g. patient selection, doses, time and route of administration of drugs/interventions. 
This would help successfully design subsequent clinical trials in which the efficacy of treatments on 
specific patient population can be evaluated conclusively.  
Guidelines such as those proposed by the ARRIVE (Animal Research: Reporting of In Vivo 
Experiments) [21] and Open Science Framework should also might help to improve the quality and 
transparency of data reporting in publications. 
 
3. The surrogate validation gap 
In a sequential approach, once robust data confirming IS-limiting effect is  obtained from animal 
experiments , performing a “proof-of-concept” clinical trial is the subsequent logical step[22]. If such 
RCT using a surrogate endpoint brings promising results, larger multicentre RCTs will be required to 
determine whether these therapeutic interventions can actually improve major clinical outcomes in 
STEMI patients treated by PPCI, leading finally to the incorporation of the novel therapy into clinical 
practice. 
In this section the focus is on the use of IS as a surrogate endpoint. Many reasons explain why it 
has been widely used to test the efficacy of cardioprotective therapies. First, IS has been historically 
recognized as the experimental hallmark of cardioprotection and can be measured using 
triphenyltetrazolium chloride staining with relative ease, although blinded analysis is required to 
avoid subjectivity in selection of lesion area. Second, IS reduction is achievable in clinical practice, as 
has been shown initially by thrombolysis and subsequently by PPCI. Third, IS reduction is considered 
a major determinant of prognosis[4]. Finally, IS has well-defined statistical characteristics: as a binary 
event (dead or alive), myocardial infarction should be a robust and unambiguous endpoint[4], 
although its measurement threshold present some difficulties and controversies (ie standard deviation 
used to define remote or at risk myocardium using magnetic resonance imaging) . However, in spite 
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of its widespread use, no true surrogacy has been established between IS and clinical outcomes, 
considering the strict criteria that are currently used [23]. 
3.1. The rationale behind the use of surrogate endpoints 
Therapies able to reduce IS are tested under the hypothesis that smaller infarctions will result in 
fewer adverse clinical events in the long-term. This paradigm is based on the assumption that the 
prognosis after an STEMI is greatly dependent on the amount of myocardium that undergoes 
irreversible injury [16].  
3.2. The lack of “strict” validation of infarct size as a surrogate endpoint 
The use of surrogate endpoints requires prior validation[23]: it should be consistently measurable 
and sensitive to the intervention, it should predict events and moreover, its response to an intervention 
should predict the response to the intervention in a RCT using clinical outcomes. As shown in  figure 
1, according to Domanski et al[24] five criteria are needed to validate a surrogate endpoint. 
Despite IS not being a true surrogate (see figure 1), we believe it is still reasonable to use it as a 
marker of clinical outcome as it can be affected by specific cardioprotective strategies and is  known 
to be associated with a biological effect. However, more attention should be paid to the increasing use 
of left ventricular systolic function as a surrogate endpoint for heart failure, since STEMI patients 
have an increasing rate of heart failure admissions as well as a decreasing mortality rate. 
3.3. Additional problems in using IS as a surrogate endpoint 
The extent of myocardial injury depends not only on duration of ischemia, but also on the location 
of the acute coronary occlusion as well as in the presence of collateral flow. Hence, IS in STEMI 
patients presents wide variations[5], although RCT on cardioprotection usually show smaller infarcts 
than those reported in clinical registries [5].  
It is unknown whether the relationship between the duration of the ischemic insult and the extent 
of myocardial necrosis is linear or, on the contrary, it follows a monotonic non-linear relationship. 
This gap in our knowledge is important in order to elucidate whether myocardial IS reduction with a 
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cardioprotective intervention is greater in patients presenting with early or late reperfusion. There is 
increasing evidence supporting the idea that the shorter the ischemic time, the greater the benefit in 
terms of myocardial salvage. Hence, those presenting with early reperfusion are most likely to benefit 
from the intervention[25]. For instance, in a RCT testing exenatide [26], myocardial salvage was 
achieved only in those patients presenting within 2–3 h of chest pain onset. On the contrary, it is also 
plausible that interventions in patients with timely reperfusion and subsequent small infarcts make no 
difference in terms of tissue salvage.  
The nature of the relationship between ischemia duration and cardiovascular death is also 
uncertain. If the surrogacy is reliable, late reperfusion is expected to result in less myocardial salvage 
and consequently in a higher mortality rate, in comparison with early reperfusion. The relationship 
between time to reperfusion and mortality as a continuous function has previously been addressed but 
with conflicting results. De Luca et al showed a linear relationship in which the risk of 1-year 
mortality is increased by 7.5% for each 30-minute delay in PPCI[27]. However, such a positive linear 
relationship has been largely criticized and it is currently accepted that the first 2-to-3h represents the 
narrowness of the “golden window”, followed by a continued mortality benefit of decreasing 
magnitude over time[28].  
Finally, it is completely unknown how potent an IS-limiting effect needs to be to have a 
meaningful impact on clinical outcomes. Potentially, no impact might be noticed until a particular IS 
threshold is achieved. In this regard, one study has suggested that a reduction of IS to <20% of the LV 
seems to be a reasonable target for an IS-limiting therapy to prevent mortality and heart failure after 
AMI[29]. Thus, this study suggested that in 25% of patients, only those with infarcts larger than 20%, 
might likely present an event in the future, subsequently representing the true population that would 
benefit from the application of a cardioprotective drug during reperfusion therapy [29]. However it is 





4. The gap in clinical studies 
4.1. Study design 
Like any experiment in the laboratory, a RCT is also defined by the controlled factors and the 
allocation of the intervention decided by the researcher. As it happens with experiments, when a RCT 
has a neutral effect (the null hypothesis is not rejected), several factors needs to be analysed to 
understand the discordance between the pre-clinical and the clinical studies. 
4.1.1. Selection of patients 
The eligibility criteria of a RCT determine the population of patients to which the trial findings 
can be extrapolated [30]. Overall, RCTs on cardioprotection have established several entry criteria in 
order to avoid treatment effect dilution. Thus, the location of the AMI has been widely used as a 
restrictive criterion, under the assumption that focusing on larger infarcts might provide further room 
to protect, as well as higher rates of cardiovascular events at follow-up. Whether these eligibility 
criteria helps to detect a real clinical benefit remains uncertain. Cardioprotective therapies have 
mostly shown successful results in reduction of infarct size studying anterior infarcts. For instance, 
metoprolol proved effective when applied in this setting [31], but failed to demonstrate 
cardioprotection in a non-restricted population[32]. In any case, restricting patient selection has to be 
balanced with the potential application of the result to a broad spectrum of STEMI patients.  
4.1.2. Baseline clinical characteristics of the patients 
A recurrent issue in our field is whether baseline clinical characteristics have a meaningful impact 
on the results. Major determinants of IS including duration of ischemia, area at risk and collateral 
blood flow; are expected to be well distributed in the selected patients and treatment arms due to the 
randomized allocation and appropriate sample size.  
4.1.3. Timing of treatment 
Any cardioprotective intervention can be given prior to or at the time of PPCI to reduce 
myocardial IS and preserve LV systolic function, thereby potentially improving survival and 
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preventing heart failure in reperfused STEMI patients. Thus, treatment might be administered at any 
time between first patient contact and time of reperfusion, either using oral, intravenous or an 
intracoronary route. 
Unlike administering the intervention at the time of PPCI (in the cath lab), it seems more 
beneficial to do so at an earlier time-point, in the ambulance whilst in transit to the PPCI centre, as has 
been demonstrated in several proof-of-concept clinical studies on RIC [33], glucose-insulin-potassium 
therapy[34] and metoprolol[31,35]. In fact, two recent sub-analyses on metoprolol and remote 
ischemic conditioning suggest a larger IS reduction when therapy is applied early [36,37]. 
4.1.4. Primary endpoints 
Composite primary endpoints comprising several nonfatal events, such as MI and stroke along 
with cardiovascular mortality, are commonly used in RCT of STEMI [38]. Inclusion of some extra 
components such as unstable angina or ischemia-driven revascularization to the composite endpoint 
provide broader major adverse CV events composite. This would boost the numbers of events but 
may dilute the effect and meaning of the composite, since the most frequent event is often least 
clinically relevant. Moreover, not all these major adverse cardiac events equally reflect the myocardial 
IS-limiting effect of the intervention. Thus, events such as stroke and coronary revascularization are 
less likely to be influenced by a myocardial IS-limiting study intervention than rates of cardiac death 
and hospitalization for heart failure[39]. Also, the outcome optimization always needs to be placed in 
perspective alongside costs. The CIRCUS trial (Cyclosporine to ImpRove Clinical oUtcome in ST-
elevation myocardial infarction patients), a multicenter double-blind RCT studying the clinical impact 
of cyclosporine, a mitochondrial permeability transition pore inhibitor, illustrates perfectly the 
problem of RCTs on cardioprotection when trying to balance the chosen outcomes and the costs 
involved[40]. Although this RCT was originally conceived for the composite of death or re-
hospitalization for heart failure as the primary outcome, two new outcomes (worsening of heart failure 
during the initial hospitalization and adverse left ventricular remodeling within 1 year) were added to 
the criteria due to limited funding and resultant necessity to reduce the sample size. 
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To sum up, the effect of cardioprotective interventions may be diluted when including soft events 
(see above) into composite primary endpoints. This issue might be addressed with a win ratio 
approach, in which not all outcomes from the composite have the same weight[41]. It is also needed 
to balance the cost of an increasing sample size with outcome benefit.  
4.1.5. Sample size 
The progressive drop of event rates in the last decades due to the increasing use of evidence-based 
therapies[40] has made it unpredictable and harder to achieve the expected event rate in both the 
control and the intervention group of any RCT conducted in STEMI patients. Moreover, the absolute 
risk of a poor outcome in RCT control groups is usually lower than in real-world registries. In general, 
RCT patients have different baseline characteristics with regard to age, comorbidities, and drug 
treatments, and accordingly, have a lower mortality and lower event rate than non-participants[30]. 
For instance, in a recent registry of patients treated with PPCI for STEMI[42], the 1-year mortality 
rate was 11.4%, whilst in the recently published CIRCUS trial it was about 7%[40]. In the same way, 
some studies might be considered underpowered due to an unexpected small infarct size. Hence, the 
EARLY-BAMI trial which was powered to detect a reduction in IS from 28% to 23.5%, showed that 
the final estimated IS was actually 15.1%. This is a major concern, since RCT statistical power 
depends mainly on the total number of patients in the trial experiencing the primary event at follow-
up. 
In general, RCTs on cardioprotective therapies have presented small sample sizes, compared to 
other RCTs showing clinical benefits on STEMI patients. For instance, the GUSTO-1 (Global 
Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), 
which compared four thrombolytic strategies, included 41000 patients[43], whilst RCT on 
cardioprotection barely include more than 1000 patients.  
In this context, it is important to state that, the smaller the RCT, the larger the magnitude of 




4.2. The reality checkpoint 
The “real” gap is composed of all these factors that can mitigate the effect of any cardioprotective 
strategy being tested and, consequently, confound the interpretation of the results of RCTs. It might 
be also defined as the reality checkpoint, given that most of these factors are unavoidable barriers to 
deal with for any potential successfully translated cardioprotective intervention. 
4.2.1. Major confounding factors before reperfusion 
4.2.1.1. Cardiovascular risk factors and co-morbidities 
STEMI is a disorder associated with multiple cardiovascular risk factors and co-morbidities, 
including hypertension, hyperlipidemia, diabetes, and aging.  
Experimental and clinical evidence suggest that these co-morbidities induce alterations in 
myocardial cellular signalling cascades, thereby affecting both the sensitivity to IRI and the response 
to a particular cardioprotective strategy [44,45]. 
Many examples can be found in experimental and clinical studies to illustrate this fact. For 
instance, hyperlipidemia is associated with the loss of cardioprotection by IPC in rabbits and 
rats[46,47], as well as in patients who underwent elective PCI [48,49]. Hypertension has been 
associated with the loss of effect of IPOST in rats [50] as well as with the attenuation of the 
prodromal angina effect in patients with an anterior STEMI [51]. Diabetes mellitus makes the heart 
more susceptible to IRI and less sensitive to the cardioprotective effect of IPC and IPOST [45,52–54]. 
In the same line, the benefits of prodromal angina on IS reduction has been blunted in diabetic 
patients presenting with anterior STEMI [55]. Finally, aging changes both the pharmacokinetics and 
pharmacodynamics of cardiovascular drugs[56] as well as affects the susceptibility to be 
protected[45]. As demonstrated in other co-morbidities, the cardioprotective effect of angina in the 24 
hours before AMI is lost in elderly patients [57]. 
5.1.2. Concomitant chronic medication  
The use of concomitant chronic medication prior to the STEMI might have an important influence 
in the final outcome, by either blocking or inducing cardioprotection themselves. 
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Aspirin and statins are widely used to prevent cardiovascular events in primary prevention, 
increasing the likelihood of STEMI patients to be on these drugs before the ischemic episode. 
Interestingly, long-term statin therapy before PPCI has been associated with smaller IS and higher 
myocardial salvage[58]. 
Anti-diabetic medication deserves special attention, not only due to their increased use in STEMI 
patients but also because of their potential deleterious effects on cardiac tissue response. Whilst some 
anti-diabetics such as sulfonylureas may further impair IRI damage in diabetic patients[53], several 
experimental studies have suggested that metformin and dipeptidyl peptidase-4inhibitor drugs protect 
against IRI[59,60]. 
The sodium–glucose cotransporter 2 inhibitors, when administered alongside the standard care, 
has been recently shown to reduce cardiovascular death in patients with type 2 diabetes, making this 
class of drug an interesting target to be studied in the context of cardioprotection[61]. 
5.1.3. Concomitant acute adjunctive medication during STEMI 
Many standard interventions in clinical practice may either attenuate IS or potentially reduce 
patient morbidity and mortality, making it increasingly difficult to successfully translate newer 
cardioprotective interventions.  
Some coronary strategies might blunt the effect of any other intervention being tested – eg 
technical improvements in catheterization, stenting, distal protection, and thrombus aspiration; may 
help minimising the extent of injury caused during the interventions [39]. 
Aspirin, surprisingly, does not seem to protect when administered acutely[62] and its interaction 
with other drugs may even have a deleterious effect. For example, it has been found that low-doses of 
aspirin administered before reperfusion abolish the IS-limiting effect of morphine[62] as well as 
blunting the cardioprotective effect of atorvastatin in rats[63]. However, clinical benefits are 
augmented by supplementing aspirin with new antiplatelet agents such as clopidogrel, ticagrelor, or 
prasugrel[64–66]. Their clinical benefits have mainly been attributed to their antiplatelet effect, 
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although an increasing body of evidence shows their important role on IS reduction [67] via 
mechanisms involving nitric oxide and adenosine [15,68]. 
Anticoagulants are another class of medication widely used in STEMI patients and should be 
considered when interpreting RCT on cardioprotection. On one hand, heparin may have 
cardioprotective effects independently of its antithrombin mechanism[69,70], but may potentially 
mitigate further protective effects. On the other hand,  heparin has been associated with reduction of 
future cardiovascular events[71,72], making it increasingly difficult to detect potential clinical 
benefits. The use of other anticoagulants, such as  bivalirudin, may also an impact on adverse clinical 
events reduction[73,74]. 
Intravenous morphine administration is recommended by guidelines for pain relief in patients 
with active ischemia[75]. Opioids such as morphine have been shown to protect the heart and limit IS 
in various animal models[76], their impact in STEMI patients is as complex as unpredictable given its 
effect in delaying the availability of other orally administered drugs[77] although this has been 
disputed in a few recent paper [78,79].  
4.2.2. Major confounding factors after reperfusion 
Overall, event rates have dropped in STEMI patients and, as evidence-based medicine has grown, 
it has become increasingly difficult to demonstrate incremental benefit beyond that which has already 
been achieved. For instance, early mortality of STEMI patients has decreased from 20% in the late 
1980s to 5% in 2008[80,81], although national registries have shown variation across regions[82]. 
Similarly, late mortality has also experienced great changes, largely falling over time in those STEMI 
patients who have undergone PPCI[42].  
The main consequence of this huge improvement over the years is that very large sample sizes on 
RCT are now required to demonstrate that a new treatment improves clinical outcomes[42]. 
The significant improvement observed in mortality may be attributable in a large part to the use of 
chronic cardiovascular medications after STEMI[83]. These secondary prevention therapies, such as 
angiotensin-converting enzyme inhibitors, aldosterone antagonists, β-blockers, and statins have 
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sizeably improved patient prognosis[84], making it increasingly difficult to add clinical benefits on 
top of contemporary state-of-the-art therapy.  
In spite of these improvements, mortality in post-STEMI patients still remains high and there is 
no evidence that a plateau on clinical outcomes improvement has been achieved. Moreover, morbidity 
of post-STEMI survivors has increased, resulting in a higher prevalence of patients with significantly 
impaired LVEF and subsequent chronic heart failure. Both mortality and morbidity consequences of 
IRI are an unmet socioeconomic burden that needs to be addressed with the development of further 
and better cardioprotective strategies.  
 
5. Looking towards the future – summary  
 Morbidity and mortality after a STEMI still remain significant. The development of new 
strategies for cardioprotection which can further reduce myocardial IS and improve clinical outcomes 
is still an unmet need. Further efforts are required to address the gaps in the pre-clinical setting, in the 
use of surrogate endpoints, in designing clinical outcomes studies as well as in testing the therapies in 
the complex clinical setting. Tackling these gaps might increase the chances to successfully translate 
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Table 1  
The translational journey of some specific cardioprotective therapies in STEMI patients 
Therapeutic 
intervention 
Pre-clinical knowledge Surrogate outcome studies Clinical outcome results Potential reasons for neutral results 
in the clinical setting 
 
Nicorandil Nicorandil given just before IRI reduced 
IS in a dog model [85] 
 
Main mechanism: combination of  
ATP-sensitive potassium channel opener 
and nitrate preparation 
J-WIND-KTP trial [86] tested the 
administration of nicorandil started 
after reperfusion, demonstrating no 
difference in myocardial IS measured 
using biomarkers or 6 month LVEF 
No data - Not only anterior STEMI 




GIK slows the progression of IRI in 
many experimental settings [87] 
 
Main mechanism: promotion of glucose 
metabolism 
IMMEDIATE trial [34] demonstrated a 
reduction in myocardial IS with no 
difference in progression to myocardial 
infarction 
CREATE-ECLA[88] 
showed no differences in 
mortality at 30 days 
 
 
- IV GIK infusion for 24h started after 
reperfusion in the majority of cases 
- Not only anterior STEMI 






ANP given just prior to reperfusion 
reduced IS in rabbit hearts [89] 
 
Main mechanism: ANP targets 
prosurvival kinase pathways such as the 
cGMP and RISK pathways 
J-WIND-ANP: Intravenous carperitide 
(an ANP analogue) starting prior PPCI 
reduced IS measured by biomarker 




No data - Further studies are needed to 
determine whether carperitide has an 




Prior to index ischemia, adenosine 
reduces IS in animal models of acute IRI 
[90]. Whether it can also be effective 
when administered at the time of 
reperfusion is less clear. 
 
Main mechanism: 
nitric oxide and protein kinase G 
AMISTAD study reported reductions 
in IS with high-dose intravenous 
administration[91], whilst PROMISE 
study [92]failed to show reproduce the 
results using lower doses of 
intracoronary adenosine 
No data - Doses and route of administration 





Pre-clinical knowledge Surrogate outcome studies Clinical outcome results Potential reasons for neutral results 
in the clinical setting 
 
IPOST IPOST has demonstrated to be capable of 
reduce both myocardial IS and coronary 
microvascular obstruction [93] 
 
Main mechanism: 
Delayed reversal of acidosis and  
activation of pro-survival cascades 
Significant reduction in biomarkers 
release, increase in LVEF and 
reduction in myocardial IS by 
SPECT[94,95]  
DANAMI 3-iPOST has 
failed to demonstrate 
clinical benefit using a 
composite endpoint of 
all-cause mortality and 
hospitalization for 
congestive heart failure * 
- Risk of coronary microembolization 
- Potential influence of concomitant 
co-morbidities and co-treatment on 
the ischemic conditioning response 
RIC Consistent evidence among diverse 
models and species that RIC confers 
cytoprotection against IRI[96] 
 
Main mechanism: 
Neural and/or humoral signalling 
Increase in the myocardial salvage 





study [97] is expected to 
recruit 4300 patients 
(NCT01857414) 
 
Cyclosporin  Cyclosporin has demonstrated to reduce 
IS in many studies, with some 
contentious results [19] 
 
Main mechanism: inhibition of MPTP 
opening 
Significant reduction in 72h AUC, 
increase in LVEF and reduction in 
myocardial IS by CMR [98], although 
very recently the CYCLE study [99] 
failed to demonstrate enzymatic IS 
reduction and ST-segment resolution 
CIRCUS trial [40] failed 
to improved clinical 
outcomes at 1 year in 
anterior STEMI patients 
- Total ischemic times were relatively 
prolonged (4.5h) 
- Dose and route of administration 
Exenatide Exenatide has resulted cardioprotective 
in both small and large animal 
models[100,101] 
 
Main mechanism: GLP-1 analogy, 
NO/cGMP signalling pathway 
Increase in the myocardial salvage 
index at 90 days by CMR[102] 
 
No data - Further studies are needed to 
determine whether exenatide has an 
impact in clinical outcomes 
Metoprolol Metoprolol reduced myocardial IS and 
preserve LV systolic function in a swine 
model [103] 
 
Main mechanism: unknown, although it 
seems to extend beyond their effect on 
hemodynamics and oxygen consumption 
 
METOCARD-CNIC trial [31] 
administered in the ambulance reduced 
IS and preserved LV systolic function  
EARLY BAMI trial [32] has recently 
reported that early intravenous 
metoprolol before PPCI was not 
associated with a reduction in infarct 
size in a non-restricted STEMI 
population 
Move On! Trial [104] 
plans to investigate the 
effect of metoprolol on 
mortality and heart 
failure hospitalization 
- the largest trial has been performed 
in all AMI locations, whilst the 
positive effects had been shown in 
anterior infarcts 
- the timing of drug administration 
might be of major importance, as a 
substudy reveals that the sooner 
metoprolol is administered in the 
course of infarction, the smaller is the 





Pre-clinical knowledge Surrogate outcome studies Clinical outcome results Potential reasons for neutral results 
in the clinical setting 
 
Hypothermia Hypothermia can reduce IS either 
starting before ischemia, during ischemia 
or immediately at reperfusion [105] 
 
Main mechanism: energy preservation 
(reduction of metabolic demands) 
 
CHILL-MI trial [106] failed to 
demonstrated an overall IS reduction 
using hypothermia, although patients 
with an anterior STEMI presenting 
within 4 h benefited from the therapy 
No data - the main limitation to translate the 
therapy is the technology: further 
devices capable of inducing 
hypothermia at a faster rate are 
needed 
TRO40303 Reduction of  myocardial IS when 
administered at time of reperfusion in 
small-animal model[107], although 
failing in a large-animal model[108] 
 
Main mechanism: inhibition of MPTP 
opening by attenuating ROS production 
MITOCARE study[109] failed to show 
IS reduction and increased myocardial 
salvage, using biomarkers and CMR 
respectively 
No data - Not enough pre-clinical evidence 
- Formulation and dosage of 
TRO40303 used in the clinical setting 
differed from pre-clinical studies 
- Difference between groups in TIMI-
flow of culprit artery after PCI (12.1% 
in the TRO40303-group vs 6.3% in 
the placebo-group) 
 
*Presented by Dr. Thomas Engstrøm at the American College of Cardiology Annual Scientific Session, Chicago, IL, April 3, 2016.  
Acronyms: AMISTAD (The Acute Myocardial Infarction STudy of ADenosine); CHILL-MI (AMI: Rapid Endovascular Catheter Core Cooling Combined With Cold Saline 
as an Adjunct to Percutaneous Coronary Intervention for the Treatment of Acute Myocardial Infarction); CIRCUS (Cyclosporine to ImpRove Clinical oUtcome in ST-
elevation myocardial infarction patients); CREATE-ECLA (Clinical Trial of MEtabolic Modulation in Acute Myocardial Infarction Treatment Evaluation-Estudios 
Cardiologicos Latinoamerica); CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction); DANAMI 3-iPOST (Third DANish Study of Optimal Acute 
Treatment of Patients with ST-segment Elevation Myocardial Infarction: Ischemic Postconditioning During Primary PCI); EARLY-BAMI (Early- Beta-blocker 
Administration before primary PCI in patients with ST-elevation Myocardial Infarction); IMMEDIATE (Immediate Myocardial Metabolic Enhancement During 
Initial Assessment and Treatment in Emergency Care); K-WIND-ANP (Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by 
ANP); K-WIND-KTP (Japan-Working groups of acute myocardial infarction for the reduction of NecroticDamage by a K-ATP channel opener); METOCARD-CNIC (Effect 
of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion); MITOCARE (Multicenter, randomized, double-blind, placebo controlled study to assess 
safety and efficacy of TRO40303 for reduction of reperfusion injury in STEMI patients undergoing primary PCI); MOVE ON! (Impact of Pre-Reperfusion Metoprolol on 
Clinical Events After Myocardial Infarction); PROMISE (protection with adenosine during primary PCI in patients with STEMI) 
Abbreviations: ANP, atrial natriuretic peptide; GIK, Glucose-insulin-potassium; IS, infarct size; IPOST, ischemic postconditioning; IRI, ischemia/reperfusion injury; LVEF, 
left ventricular ejection fraction; MPTP, mitochondrial permeability transition pore; PPCI, primary percutaneous coronary intervention; RIC, remote ischemic conditioning; 
ROS,   reactive oxygen species; SPECT, single photon emission computed tomography; STEMI, ST-segment elevation myocardial infarction;
Table 2  
Major differences between pre-clinical animal MI models and the typical patient presenting with an 
acute MI treated by myocardial reperfusion. 
Factor Animal models STEMI patients Potential improvements 
Subject Usually young small 
animals 
Middle aged patients Use aged large and old 
animals 
Timing of the 
intervention 
Similar in all animal 
models (prior to 
ischemia or upon 
reperfusion) 
It varies between 
patients 
In clinical studies, 
interventions should be 
administered according to 
those results reported in the 
experimental setting 
Infarct size Varies from 30% to 
60% of the total left 
ventricular mass 
Infarcts are smaller, 
limiting the room for 
cardioprotection 
Clinical study designs 
should consider this 
difference when calculating 
sample size 
MI model Most studies use 




rupture, other coronary 
arteries affected, 
inflammatory response 
Use animal models of 
coronary atherosclerosis.  




Use animal models of 








and chronic medication 
Use of models conducted on 





Fixed and usually 
short 
Continual reperfusion Use longer reperfusion 
periods 





Fig. 1. Application of the five accepted criteria to validate IS as a true surrogate endpoint. 
Abbreviations: PPCI, primary percutaneous coronary intervention; STEMI, ST-segment elevation 
myocardial infarction. 
 
